19.11.2025 12:40:19 CET | Demant A/S |
Investor Nyheder
Investor news
19. november 2025
Demant opnår regulatorisk godkendelse af opkøb af KIND
I juni 2025 meddelte Demant, at koncernen havde indgået en aftale om at opkøbe KIND Group (KIND), som er en af verdens førende forhandlere af høreapparater med omkring 650 høreklinikker. Pr. dags dato er alle regulatoriske betingelser opfyldt, hvilket omfatter godkendelser fra både de østrigske og tyske konkurrencemyndigheder.
Da de regulatoriske betingelser nu er opfyldt, udestår der opfyldelse af sædvanlige betingelser, før parterne kan lukke transaktionen. Dette forventes at ske i begyndelsen af december 2025, hvor vi vil kunne give nærmere oplysninger om, hvilken økonomisk betydning integreringen af KIND i Demant vil få.
Yderligere information:
Søren Nielsen, koncernchef & adm. direktør
Telefon +45 3917 7300
www.demant.com
Øvrige kontaktpersoner:
René Schneider, CFO
Peter Pudselykke, Head of Investor Relations
Gustav Høegh, Investor Relations Officer
Henrik Axel Lynge Buchter, Manager of External Communications
Kontakter
Henrik Axel Lynge Buchter, External Communication Manager, Corporate Communication & Sustainability, +45 2264 9982, heey@demant.com
Om Demant A/S
Demant is a world-leading hearing healthcare group that offers innovative technologies, solutions and expertise to help people hear better. In every aspect, from hearing care and hearing aids to diagnostic equipment and services, Demant is active and engaged. Headquartered in Denmark, the Group employs more than 22,000 people globally and is present with solutions in 130 countries creating life-changing differences through hearing health. William Demant Foundation holds the majority of shares in Demant A/S, which is listed on Nasdaq Copenhagen and among the 25 most traded stocks.
Vedhæftninger
Investor news – Demant opnår regulatorisk godkendelse af opkøb af KIND.pdf
19.11.2025 12:40:19 CET | Demant A/S |
Investor News
Investor news
19 November 2025
Demant obtains regulatory approval for the acquisition of KIND
In June 2025, Demant announced an agreement to acquire KIND Group (KIND), one of the world’s leading retailers of hearing aids with around 650 hearing care clinics. As of today, all regulatory conditions have been fulfilled, which include approvals by both the Austrian and German competition authorities.
With the regulatory conditions now in place, the customary closing conditions remain outstanding, before the parties can close the transaction. This is expected to take place at the beginning of December 2025, at which time we will communicate the financial implications of consolidating KIND into Demant.
Further information:
Søren Nielsen, President & CEO
Phone +45 3917 7300
www.demant.com
Other contacts:
René Schneider, CFO
Peter Pudselykke, Head of Investor Relations
Gustav Høegh, Investor Relations Officer
Henrik Axel Lynge Buchter, Manager of External Communications
Contacts
Henrik Axel Lynge Buchter, External Communication Manager, Corporate Communication & Sustainability, +45 2264 9982, heey@demant.com
About Demant A/S
Demant is a world-leading hearing healthcare group that offers innovative technologies, solutions and expertise to help people hear better. In every aspect, from hearing care and hearing aids to diagnostic equipment and services, Demant is active and engaged. Headquartered in Denmark, the Group employs more than 22,000 people globally and is present with solutions in 130 countries creating life-changing differences through hearing health. William Demant Foundation holds the majority of shares in Demant A/S, which is listed on Nasdaq Copenhagen and among the 25 most traded stocks.
Attachments
Investor news – Demant obtains regulatory approval for the acquisition of KIND.pdf
